Novartis Books $2.2 Billion Hit From Trial Setbacks, Lifts Guidance
Novartis reported a $2.2 billion hit from drug trial setbacks and lifted its guidance.
Related stories
Cognizant Cuts Upper End of FY26 Revenue Guidance as Q3 Bookings Fall 7%
Cognizant lowered the upper end of its full-year 2026 revenue growth forecast after bookings fell 7% year over year in the September quarter. Revenue exceeded Wall Street estimates
M impact | EARNINGS | Oct 30, 2026, 03:01 AM UTC
Shanghai International Port Group Shares Jump 5.3%
Shanghai International Port Group shares rose as much as 5.3% in Friday morning trading. The company said third-quarter net profit increased by more than four-tenths year over year
M impact | EARNINGS | Oct 30, 2026, 02:49 AM UTC
Haier Smart Home 3Q Revenue Falls 10% to CNY69.70B
Haier Smart Home reported third-quarter revenue of CNY69.70 billion, down 10% year over year.
M impact | EARNINGS | Oct 30, 2026, 02:48 AM UTC
Haier Smart Home 3Q Net Profit Falls 12% to CNY4.68B
Haier Smart Home reported third-quarter net profit of CNY4.68 billion, down 12% year over year.
M impact | EARNINGS | Oct 30, 2026, 02:48 AM UTC
GC MediAI Raises 2026 Operating Profit Forecast to KRW 17 Billion
M impact | EARNINGS | Oct 30, 2026, 02:41 AM UTC
Daito Trust Construction Reports Six-Month Group Net Profit Growth
The company forecast higher profit for 2026/27.
M impact | EARNINGS | Oct 30, 2026, 02:31 AM UTC